The NCI Office of Cancer Centers Learning Series

Bringing Science to the Marketplace:
The NCI SBIR Program

Dial In: **800-593-9924**
Passcode: CANCER CENTERS

For Technical Support, call **800-857-8777** and choose **option 3**.

The NCI Office of Cancer Centers Learning Series

Bringing Science to the Marketplace:

The NCI SBIR Program

Thursday, September 8, 2011
2:00 to 3:30 pm EDT

Moderator

Shannon L. Silkensen, PhD
Program Director
Office of Cancer Centers
National Cancer Institute
National Institutes of Health
Bethesda, MD

Featured Presenters

Michael Weingarten, MA
Director
SBIR Development Center, NCI
Bethesda, MD

David Beylin, MS, MBA, DABSNM
SBIR Program Director
SBIR Development Center, NCI
Bethesda, MD

James Olson, MD, PhD
President and Founder, Presage Biosciences
Full Member, Fred Hutchison Cancer Center
SBIR Program Grantee
Seattle, WA

A Quick Guide to Your Screen

- Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging the dropdown box to the right side of your screen.



Bringing Science to the Market: The NCI SBIR Program

NCI Cancer Centers Learning Series

September 8, 2011

Michael Weingarten
Director, NCI SBIR Development Center

Today's Presentation

- General SBIR/STTR Program Overview
- NCI/NIH SBIR Funding Opportunities
- NCI Phase II Bridge Award
- Program Initiatives

Percent of NCI and NIH Budget

SBIR & STTR

	Set Aside
SBIR: Set-aside program for small business concerns to engage in Federal R&D with the potential for commercialization	**2.5%**
STTR: Set-aside program to facilitate cooperative R&D between small business concerns and U.S. research institutions with potential for commercialization	**0.3%**

~$109 million annually at the NCI

~$650 million annually at the NIH

Why are SBIR and STTR Important to NCI?

- **NCI's primary resource for enabling commercialization of high impact technologies that can benefit patients, such as:**
  - **Small Molecules and Biologics**
  - **Cancer Diagnostics**
  - **Cancer Imaging**
  - **Electronic Health & Education Tools**

Reasons to seek SBIR & STTR Funding

- **One of the largest sources of early stage of life sciences funding in the country.**
  - **A stable and predictable source of funding**
- **Intellectual property rights are retained by the small business concern**
- **Not a loan – no repayment is required**
- **Doesn't impact stock or shares in any way (no dilution of capital)**
- **Provides recognition, verification and visibility**
- **Can be a leveraging tool to attract other funding (VC, etc.)**

SBIR Eligibility Requirements

SBIR & STTR

Small Business Concern

- **For-profit U.S. business**
- **500 or fewer employees, including affiliates**
- **Must be:**
  - **At least 51% owned by US individuals and independently operated**

    or
  - **At least 51% owned and controlled by another business concern that is at least 51% owned and controlled by one or more individuals**
- **Principal Investigator's primary employment must be with the Small Business Concern at the time of award**

STTR Eligibility Requirements

- **Applicant is a Small Business Concern**
- **Formal Cooperative R&D Effort**
  - **Minimum 40% by small business**
  - **Minimum 30% by U.S. research institution**
- **U.S. Research Institution**
  - **College or University**
  - **Other non-profit research organization**
  - **Federal R&D center**
- **Intellectual Property Agreement**
  - **Allocation of IP rights and rights to carry out follow-on R&D and commercialization**
- **Principal Investigator's primary employment may be with either the Small Business Concern or the research institution**

SBIR & STTR: Three-Phase Programs

PHASE I – R41, R43

- **Feasibility Study**
- **$150-250K, 6-12 months**



PHASE II – R42, R44

- **Full Research/R&D**
- **$1-2M, 2-3 years**
- **Commercialization plan required**



PHASE III

- **Commercialization Stage**
- **Use of non-SBIR/STTR Funds**

** These funding levels are guidelines. Companies should request the budget appropriate to accomplish the goals of the project.*

NCI SBIR Funding Opportunities

SBIR Portfolio Summary *(Active as of July 1 2010)*

Grants & Contracts -- $109M budget

SBIR & STTR

Classification	Topic Area	Phase I (% of portfolio)	Phase II (% of portfolio)
Therapeutics 31%	Biologics	28 (6%)	19 (4%)
	Small molecules	59 (12)	18 (4)
	Nanotechnology-based therapeutics	15 (3)	9 (2)
Devices for Cancer Therapy 9%	Surgical interventions	4 (1)	3 (1)
	Ablative technologies	6 (1)	3 (1)
	Radiation Therapy	12 (2)	15 (3)
Imaging Technologies 19%	Image-guided interventions	4 (1)	10 (2)
	New imaging technologies	28 (6)	49 (10)
Diagnostics 24%	*In vitro* diagnostics	63 (13)	53(11)
Cancer Biology 6%	Research Tools	13 (3)	13 (3)
Cancer Control & Epidemiology 12%	Software, Bioinformatics & eHealth	10 (2)	25(5)
	Educational Tools & Other	4 (1)	17 (4)
	Total (480)	246 (51)	234 (49)

SBIR Solicitations

SBIR/STTR Omnibus Grant Solicitation (NIH)

Release: **January**

Receipt Dates: **April 5, August 5, and December 5**

Technology Areas: ***All, investigator-initiated R&D***

Other Program Announcements, RFAs

E.g. Image-Guided Cancer Interventions (NCI)

Program Announcement #: **PA-10-079, PA-10-080**

Release: ***January 2010***

Receipt Dates: **April 5, August 5, and December 5**

Technology Areas: **IGD, IGT, IGS**

SBIR Contract Solicitation (RFP - NIH, CDC)

Release: ***New RFP August 2011***

Receipt Date: **November 7, 2011**

Technology Areas: ***Published in the RFP***

http://sbir.cancer.gov

SBIR & STTR

NCI SBIR Phase II Bridge Award

SBIR & STTR: Three-Phase Program

PHASE I – R41, R43

- **Feasibility Study**
- **$150-250K, 6-12 months**



PHASE II – R42, R44

- **Full Research/R&D**
- **$1-2 million and 2-3 year Award (SBIR & STTR) ***
- **Commercialization plan required**

Phase II Bridge Award



PHASE III

- **Commercialization Stage**
- **Use of non-SBIR/STTR Funds**

* Note: Actual funding levels may differ by topic.

SBIR Phase II Bridge Award

Follow-on to SBIR Phase II

- **Helps early-stage companies cross the "Valley of Death" by:**
  - Facilitating partnerships with third-party investors & strategic partners
  - Incentivizing third-party investments earlier in the development process
    - ➢ **NCI is sharing in the investment risk with other investors**

Incentive Structure

- **Gives competitive preference and funding priority to applicants that can raise third-party funds (i.e., 1:1 match)**
  - Affords NIH the opportunity to leverage millions in external resources
  - Provides valuable input from third-party investors in several ways:
    1. Rigorous commercialization due diligence prior to award
    2. Commercialization guidance during the award
    3. Additional financing beyond the Bridge Award project period

Bridge RFA Highlights

Mechanism & Budgets

- Uses the SBIR Phase II (R44) competing renewal mechanism
- **Provides up to $1 M per year for up to 3 years**
- Available to current Phase II grant awards, and those that ended within last 2 years

Preferred Third-Party Matching Funds

- Cash equity investment
- Contract from strategic partner (partner helps to commercialize)

Sources of Funds

- Another company, venture capital firm, individual “angel” investor, foundation, university, state or local government, or any combination

Example: How the Bridge Award Would Apply in the Area of Drug Development

SBIR Bridge Award addresses the problem by bridging the "Valley of Death"

SBIR Bridge Award allows NIH to share investment risk by incentivizing investors or strategic partners to evaluate projects and commit funds much earlier

Example: How the Bridge Award Would Apply in the Area of Drug Development

SBIR & STTR

Target Identification & Validation | Preclinical Development (Lead Development, Animal Studies, File IND) | Safety Review | Clinical Trials | NDA Review | Commercialization

Phase I & Phase II SBIR | SBIR Bridge Award | Private Investment



Ten Bridge Awards: FY09/FY10

SBIR & STTR

FY	Company	Technology/Product	Award Size
2009	**Lpath Therapeutics**	Humanized monoclonal antibody for treatment of prostate cancer	$3,000,000
2009	**Optosonics**	Photoacoustic CT for preclinical molecular imaging	$2,997,247
2009	**Guided Therapeutics**	Fluorescence/reflectance spectroscopy for detection of cervical cancer	$2,517,125
2009	**Koning Corporation**	High-performance breast CT as diagnostic adjunct to mammography	$2,986,453
2009	**Gamma Medica-Ideas**	Molecular imaging to detect metabolic activity of breast lesions	$3,000,000
2009	**Altor BioScience**	Tumor-targeted immunotherapy for treatment of p53-positive cancers	$2,969,291
2010	**20/20 GeneSystems**	mTOR companion diagnostic assay	$2,750,000
2010	**Advanced Cell Diagnostics**	*In situ* RNA detection assay for analyzing circulating tumor cells	$2,996,450
2010	**Ambergen**	Expression-based prognostic assay for recurrence of colorectal cancer	$2,998,830
2010	**Praevium Research**	High-performance imaging engine for optical coherence tomography	$1,180,420
		Total	$27,395,816

↓

2 therapeutics

5 imaging technologies

3 diagnostics

New Paradigm for Managing SBIR at NCI

SBIR Development Center Staff

Michael Weingarten, MA *(Director)*

Previous

- **NASA** – Program Manager, NASA Technology Commercialization Program

Greg Evans, PhD *(Branch Chief)*

Previous

- **NHLBI/NIH –** Program Director, Translational and Multicenter Clinical Research in Hemoglobinopathies
- **NHGRI/NIH –** Senior Staff Fellow

Patti Weber, DrPH *(Program Director)*

Previous

- **International Heart Institute of Montana –** Tissue Engineering and Surgical Research
- **Ribi ImmunoChem Research, Inc.** – Team Leader, Cardiovascular Pharmacology

David Beylin, MS, MBA *(Program Director)*

Previous

- **X/Seed Capital Management, LLC,** Consultant
- **Naviscan PET Systems, Inc.,** Vice President, Research

Deepa Narayanan, MS *(Program Director)*

Previous

- **Naviscan PET Systems, Inc.,** Director, Clinical Data Management (Oncology Imaging & Clinical Trials)
- **Fox Chase Cancer Center,** Scientific Associate (Molecular Imaging Lab)

Ali Andalibi, PhD *(Branch Chief)*

Previous

- **NSF –** SBIR Program Director, Medical Biotechnology
- **House Ear Institute –** Scientist & Director, New Technology and Project Development
- **Trega Biosciences, Inc. –** Research Scientist

Andrew J. Kurtz, PhD *(Program Director)*

Previous

- **NIH –** AAAS Science & Technology Policy Fellow
- **Cedra Corporation –** Research Associate, Bio-Analytical Assays and Pharmacokinetics Analysis

Jian Lou, PhD *(Program Director)*

Previous

- **Johnson & Johnson –** Research Scientist, Target Validation & Biomarker Development
- **Lumicyte, Inc. –** Director, Molecular Biology Systems Analysis

Todd Haim, PhD *(Program Manager)*

Previous

- **National Academy of Sciences –** Christine Mirzayan Science and Technology Policy Fellow
- **Pfizer Research Laboratories –** Postdoctoral Fellow, Cardiac Pathogenesis & Metabolic Disorders

Julienne Willis *(Program Specialist)*

NCI SBIR Investor Forum

Exclusive opportunity for 14 NCI awardees to showcase their companies to investors

http://sbir.cancer.gov/investorforum/

Featured Small Businesses

- **Present to and network with close to 200 top investors and strategic partners**
- **Participate in panel discussion with successful Bridge awardees and their investors**

Investors

- **Opportunity to evaluate NCI's top companies with innovative technologies**
- **Exclusive one-on-one meetings**
- ***Follow-Up discussions, MTA's and Due Diligence now underway***

Michael Weingarten Information

SBIR & STTR

Thank you!

Michael Weingarten
Director, SBIR Develoment Center
weingartenm@mail.nih.gov

Register for updates at http://sbir.cancer.gov

The NCI Office of Cancer Centers Learning Series

Bringing Science to the Marketplace:

The NCI SBIR Program

Questions?

Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging it to the right side of your screen.



Michael Weingarten, MA
Director
SBIR Development Center, NCI
Bethesda, MD

National Cancer Institute



SBIR Contract Solicitation, Application Tips

David Beylin, MS, MBA
NCI SBIR Development Center

CC Webinar, September 7, 2011

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

SBIR & STTR

NATIONAL CANCER INSTITUTE

NEW

FY 2012
SBIR Contract Solicitation

Funding Opportunity Summary

- **PHS-2012-1 "Solicitation of NIH and CDC for SBIR Contract Proposals"**
- **ONE application receipt date per year:** published in late August

Next Receipt Date: November 7, 2011

- **RFP can be found at:**
  - http://grants.nih.gov/grants/funding/SBIRContract/PHS2012-1.pdf
- **NCI published twelve topics (listed on the next slide) in the areas:**
  - Drugs
  - Diagnostics
  - Imaging
  - Health IT
  - Research tools

NCI Contract Funding Topics

SBIR & STTR

- 255 Development of Anticancer Agents
- (*) 277 Development of Companion Diagnostics
- (*) 291 Development of Radiation Modulators For Use During Radiotherapy
- 300 Reformulation of Cancer Therapeutics using Nanotechnology
- 301 Probing Tumor Microenvironment Using In-vivo Nanotechnology-based Sensors
- 306 Development of Innovative Algorithms for Processing & Analysis of *In Vivo* Images
- (*) 307 Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment
- 308 Automated Collection, Storage, Analysis, and Reporting Systems for Dietary Images
- 309 Development of Low Cost, Small Sample Multi-Analyte Technologies for Cancer Diagnosis, Prognosis and Early Detection
- 310 Simplified Tissue Microarray Instrument For Clinical and Research Settings (NIH Technology Transfer)
- 311 High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy (NIH Technology Transfer)
- 312 Generation and Qualification of Site-specific Post-translationally Modified Proteins for Use as Calibrators in Pharmacodynamic (PD) Assays

Example 1:
Topic 291 Radiation Modulators

- **Budget:** Phase I $200,000 ; Phase II $1,500,000
- **Number of Anticipated Awards:** 3-5
- **Project Goal:**
  - Development of radiosensitizers, radioprotectants, radiomitigators
- **Phase I work scope may include:**
  - *In vitro* testing
  - Clonogenic survival studies
  - Preliminary toxicity, etc.
- **Phase II work scope may include:**
  - *In vivo* experiments
  - PK and PD in rodent model
  - GMP drug production/sourcing, IND approval

Example 2:
Topic 307 Imaging Agents

- **Budget:** Phase I $250,000 ; Phase II $1,500,000
- **Number of Anticipated Awards:** 3-5
- **Project Goal:** Novel imaging agents for:
  - early detection of cancer
  - stratification of patients for selecting cancer therapy,
  - surgical planning
  - evaluation of tumor response to chemotherapy, radiation therapy,
  - detection of cancer recurrence, etc.
- **The work scope may include** animal testing, formulation, GMP production, pharmacokinetic, pharmacodynamic, toxicological studies, etc.

Example 3:
Topic 277 Companion Diagnostics

- **Budget:** Phase I $200,000 ; Phase II $1,500,000
- **Number of Anticipated Awards:** 4
- **Project Goal:**
  - Companion diagnostics for selecting patients for which a particular therapeutic regimen, including existing drugs and those in clinical development and radiation, will be safe and effective
- **Phase I Work Scope:**
  - Test development and analytical validation
  - If the drug is not commercially available – establish partnership w/ the source
- **Phase II Work Scope:**
  - Full clinical validation

SBIR & STTR

What does it take to get funded?

Funding

- SBIR program is highly competitive
- Commercialization potential is important
- Successful SBIR projects are product-focused

SBIR & STTR

NATIONAL CANCER INSTITUTE

Deciding to Apply

When is SBIR application appropriate?

Start-up

- Often academic spin-off
- Entrepreneur-founder with experience in the field
- Highly innovative technical solution to significant clinical need
- Significant commercial potential
- **Need more feasibility data**
- Too risky for private investors

When NOT to Apply

- **Chasing solicitations**
- **No luck with academic funding, why not apply for SBIR?**
  - SBIRs are highly competitive
- **Incremental upgrade to existing product**
- **“Me too” product matching competitor’s capabilities**
- **Product is at the stage where it needs investment significantly exceeding SBIR funding levels**

Building the Application

Strong Application: Key Components

- **Highly innovative, sound, and focused science**
- **Well designed studies**
  - **Phase I : key feasibility question**
  - **Phase II : proceed eliminating technology risks**
- **Significant commercial potential**
  - **Product-focused applications**
- **Strong team, collaborators**
  - **Appropriate for the problem**
  - **Have clinicians involved: Oncologists, Pathologists, Radiologists**
  - **Other relevant scientists/professionals, e.g. Biostatisticians**

Key Documents

Omnibus Solicitation

http://grants.nih.gov/grants/guide/pa-files/PA-11-096.html

Funding Opportunity Title	**PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])**
Activity Code	R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track
Announcement Type	Reissue of PA-10-050
Related Notices	• February 8, 2011 - See Notice NOT-AI-11-030 The purpose of this Notice is to highlight NIAID's interest in receiving grant applications to develop strategies, methods and/or tools to optimize influenza vaccine production.
Funding Opportunity Announcement (FOA) Number	**PA-11-096**

SF 424 Application Instructions

http://grants.nih.gov/grants/funding/424/index.htm



Key #1 Start Early

- **Strong proposals take time to develop**
- **Seek help early in process**
  - Engage with SBIR Program Staff
- **Need time to fill the gaps**
  - Assemble a strong scientific team
  - Get access to equipment and other resources
  - Get letters of support

Key #2 Take Time to Refine the Vision

- **Start informal discussions to clarify the product vision**
  - Potential customers
  - Technical experts
  - Potential investors & commercialization partners

- **Identify the most important technical risks**
  - Identify approaches to address those risks
  - Study design is critical

Key #3 Build the proposal team

- **Choose the Principal Investigator (PI)**
- **Consider building multi-PI team**
  - Multidisciplinary proposals
  - PI lacks certain types of necessary expertise
  - Must appoint Contact PI (SBIR, > 50% of time w/ business)
- **Identify personnel who will carry out the actual work**
- **Partner to fill the gaps**
  - Academic collaborations
  - Consultants
  - Other companies
- **Use SBIR application as engagement tool**
  - Academic researchers understand grants
  - Offer to include them on proposals as consultants/collaborators

Key #4 Reviewers only see the application

- **Specific Aims (1 page)**
  - Focal point of the application
  - Describe goals of the application
  - Accompany by quantitative performance milestones

- **Research Strategy (Phase I: 6 pages, Phase II: 12 pages)**
  - Provide background information
  - Provide detailed technical plan to achieve Specific Aims
  - Propose realistic scope/budget/timeline
  - Preliminary data not required
  - … but often powerful
  - Describe potential pitfalls and alternative angles of attack

- **Introduction (for resubmissions only, 1 page)**
  - Your response to reviewers' critiques

Key #4 Reviewers only see the application

- **Other application components**
  - Biosketches for all senior and key personnel (<4pages each)
  - Budgets for each project period
  - Separate budgets for each subcontract
  - **Phase II Commercialization Plan (Phase II, 12 pages)**
  - Descriptions of facilities and equipment
  - Letters of support
  - Human subject research section (if applicable)
  - Vertebrate animals section (if applicable)
  - Other information as required

- **Grants: SF424 R&R SBIR/STTR Application Guide**
  - Excellent source of administrative information
  - http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR_Adobe_VerB.pdf

- **Contracts: see respective Request for Proposals (RFP)**
  - E.g. http://grants.nih.gov/grants/funding/SBIRContract/PHS2012-1.pdf

Letters of Support

- **Strongly worded letters of support from:**
  - ALL consultants and collaborators
  - Those who provide access to facilities / administrators
  - KOLs who think highly of your project
  - Customers who will buy the product once it is available
  - Current or potential industry partners
  - Current or potential investors
  - Suppliers of critical technology
- **Good letter of support**
  - Explains who the writer is and why s/he is excited about proposed project
  - Explains the writer's role in the proposal
  - Contains specific support of your story/approach

Key #5 Know your reviewers

- **Who is going to review your application?**
  - Primary reviewers read your application, and lead the discussion
  - All members of the Review Panel will score your application
  - Combination of academic and industry reviewers

- **Identify the most appropriate study section BEFORE you submit your application**
  - See CSR website for SBIR/STTR study section descriptions
  - http://www.csr.nih.gov/Roster_proto/sbir_section.asp
  - Discuss study section selection with NCI SBIR Program Staff

- **What are reviewers looking for?**
  - Readable and understandable application
  - Do not assume they will know everything you know
  - Clear plan for Phase I, II and commercialization
  - Feasible, standard methods
  - Solid letters of support

More Information on NCI SBIR & STTR Website

http://sbir.cancer.gov

David Beylin Information

SBIR & STTR

Questions?

David Beylin, MS, MBA
Program Director
Phone: 301-496-0079
beylind@mail.nih.gov

Register for updates at
http://sbir.cancer.gov

The NCI Office of Cancer Centers Learning Series

Bringing Science to the Marketplace:

The NCI SBIR Program

Questions?

Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging it to the right side of your screen.

David Beylin, MS, MBA, DABSNM
SBIR Program Director
SBIR Development Center, NCI
Bethesda, MD

Presage Biosciences

Founding Presage

- 6 years of laboratory-based work
- Incorporated November, 2008
- STTR Phase I application December 2008

Feedback from Investors

- Clinical application high risk/high reward
- Challenging regulatory environment
- Too much cash at risk without proof of concept
- Nearer term commercial opportunities in pharma

Presage Today

- Helping pharma discover more efficacious drugs and drug combinations
- Already provided data to our partners to make go/no-go decisions
- Diagnostic device on track for first clinical studies in 2012
- 12 FTEs
- $7M in funding
- Multiple pharma partners

In vitro: fast, cheap, **misleading**



Presage enables use of cancer models that are better correlated to patients' actual tumors rather than artificially manipulated laboratory-based cell models.

No other known technology allows multiple comparisons in one tumor



Multiple Spatially Constrained Columns
Enable Intratumoral Comparisons

Controls for tumor heterogeneity



Active agents induce a columnar response

Presage applications



Candidate
& Indication
Prioritization

Drug
Combination
Identification



Clinical Drug
Selection

Presage *in vivo* Combos



Multiplexed, internally controlled experiments provide rapid reliable data

Combined inhibition results in synergistic anti-tumor efficacy



H&E staining



H292 lung carcinoma

Combination is tumor cell specific



Platform demonstrates context specific killing

Presage STTR History

- $361,000 Phase I application submitted Nov 2008
- $1.4M Fast Track application submitted April 2009

- Phase I Award June 2010
- Phase II Award July 2011
- NCI Investors Forum November 2010
- Regulatory Assistance Program



presage

The NCI Office of Cancer Centers Learning Series

Bringing Science to the Marketplace:

The NCI SBIR Program

Questions?

Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging it to the right side of your screen.

James Olson, MD, PhD
President and Founder, Presage Biosciences
Full Member, Fred Hutchison Cancer Center
SBIR Program Grantee
Seattle, WA

Disclosures

- Michael Weingarten: no relevant financial relationships with commercial interest.
- David Beylin: no relevant financial relationships with commercial interest.
- Jim Olson: I am a Founder and Director of Presage Biosciences. No patient trials involving Presage are open at this time.

Future OCC Learning Series Events

- **NCI Division of Cancer Treatment and Diagnosis: The Quantitative Imaging Network (QIN)**
  October 4th, 2011 2:00 to 3:30 PM EDT
  Robert J. Nordstrom, PhD

- **The Cancer Genome Atlas**
  November 1st, 2011 2:00 to 3:30 PM EDT
  Kenna Shaw, PhD

The NCI Office of Cancer Centers Learning Series

Bringing Science to the Marketplace:

The NCI SBIR Program

If you have further questions, please contact

Michael Weingarten

weingartenm@mail.nih.gov

This webinar was created by the Office of Cancer Centers in the National Cancer Institute

http://cancercenters.cancer.gov

For information about the SBIR & STTR grant program through the National Cancer Institute, please visit http://sbir.cancer.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES·USA

NATIONAL INSTITUTES OF HEALTH

NATIONAL® CANCER INSTITUTE